ArticleFrontiers in cardiovascular medicine2026
LAAEV-centric atrial failure phenotype and a novel integrative score for predicting early recurrence after AF ablation.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early recurrence of atrial tachyarrhythmia (ERAF) after radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) remains a major clinical challenge. While left atrial diameter (LAD) is a known predictor, the role of atrial mechanical function, particularly left atrial appendage emptying velocity (LAAEV), and its integration with other markers needs clarification. Methods: This single-center retrospective cohort study included 157 drug-refractory non-valvular AF patients undergoing first-time RFCA. Among them, 53 (33.8%) developed ERAF within the 90-day blanking period. Baseline clinical, echocardiographic (including LAD and LAAEV), and biochemical (NT-proBNP) data were collected. The primary endpoint was ERAF (atrial tachycardia/flutter/fibrillation ≥30 s) within the 90-day blanking period. Predictive models were developed using logistic regression. An integrative AF Recurrence Index (AF-RI) was derived and validated internally. Results: Among 157 patients, 53 (33.8%) experienced ERAF. The ERAF group exhibited a distinct "atrial failure" phenotype: larger LAD (43.8 ± 5.6 vs. 39.5 ± 4.3 mm, Conclusion: LAAEV is a potent, independent predictor of ERAF, central to an "atrial failure" phenotype. The integrative AF-RI score provides a simple, bedside-friendly tool for individualized risk stratification, enabling clinicians to identify high-risk patients (e.g., those with LAAEV < 35 cm/s) who may benefit from intensified monitoring or tailored therapeutic strategies post-ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.